Physician profile
Guillermo E Pineda
NPI 1205920709
$14,013.86
in general payments reported to CMS, 2019-2025
37 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,690 · 2020: $364 · 2021: $1,062 · 2022: $2,773 · 2023: $2,551 · 2024: $2,477 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,125.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,389.21 | 2019-2025 | Jot Dx, Amplatzer Talisman, Gallant |
| Novartis Pharmaceuticals Corporation | $1,842.24 | 2019-2025 | |
| Boston Scientific Corporation | $1,510.93 | 2019-2025 | Avvigo Guidance System, Watchman Access System, General - Atherectomy |
| Janssen Pharmaceuticals, INC | $1,041.62 | 2019-2024 | Xarelto |
| Amgen INC. | $828.91 | 2020-2025 | Repatha, Repatha |
| Pfizer INC. | $784.36 | 2019-2025 | |
| Shockwave Medical, INC | $728.62 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Merck Sharp & Dohme LLC | $627.02 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $521.45 | 2020-2025 | Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $441.31 | 2022-2025 | Camzyos, Eliquis |
| Abiomed | $401.11 | 2022-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.87 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $378.15 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $319.36 | 2022-2025 | Onpattro |
| Esperion Therapeutics, INC. | $257.62 | 2020-2025 | Nexletol |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $198.58 | 2022-2025 | (Ck4) Mcot, Event, Extended Holter |
| Bayer Healthcare Pharmaceuticals INC. | $187.34 | 2022-2025 | |
| Cardiovascular Systems INC. | $187.05 | 2019-2022 | |
| Endologix LLC | $184.27 | 2024 | Endocross Device, Torus Stent Graft System |
| Lexicon Pharmaceuticals, INC. | $111.91 | 2023-2024 | Inpefa |
| Atricure, INC. | $108.92 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Biosense Webster, INC. | $106.67 | 2019-2025 | Nuvision Ice Catheter |
| Scpharmaceuticals INC. | $100.20 | 2023-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $94.99 | 2021-2023 | Arcalyst |
| Novo Nordisk INC | $48.24 | 2024-2025 | Wegovy |
| Medtronic, INC. | $40.34 | 2023-2024 | Corevalve Evolut R, Micra |
| Bridgebio Pharma, INC. | $28.67 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $19.40 | 2021 | |
| Siemens Medical Solutions USA, INC. | $18.59 | 2022 | |
| Cardiva Medical, INC. | $18.30 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Chiesi USA, INC. | $17.99 | 2023 | Kengreal |
| Kiniksa Pharmaceuticals International, Plc | $17.14 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $16.18 | 2022 | |
| Cashflow Solutions, LLC | $15.62 | 2023 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
| Lilly USA, LLC | $14.81 | 2025 | Mounjaro, Zepbound |
| Edwards Lifesciences Corporation | $14.70 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Pineda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.